Login / Signup

Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.

Angela M C RoseFrancisco PozoIván Martínez-BazClara MazagatosNathalie BossuytJohn Paul CauchiGoranka PetrovićIsabela I LoghinRoberta VaikutyteSilke BudaAusenda MachadoRóisín DuffyBeatrix OrosziJennifer HowardAitziber EcheverriaCristina AndreuCyril BarbezangeAušra DžiugytėDiana NonkovićCorneliu-Petru PopescuFausta MajauskaiteKristin TolksdorfVerónica GomezLisa DomeganJudit Krisztina HorváthJesús CastillaMiriam GarcíaThomas DemuyserMaria-Louise BorgIrena TabainMihaela LazarIeva KubiliuteRalf DürrwaldRaquel GuiomarJoan O'DonnellKatalin KristófNathalie NicolaySabrina BacciEsther Kisslingnull nullnull null
Published in: Influenza and other respiratory viruses (2024)
We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.
Keyphrases
  • randomized controlled trial
  • systematic review
  • newly diagnosed
  • end stage renal disease
  • emergency department
  • ejection fraction